Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.50 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.50 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.50 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.50 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.50 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.50 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.49 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.49 |
| ▸ | PRKX | P51817 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19510882 | 0.95 | ROCK1 (0.53) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL25214219 | 0.91 | ROCK1 (0.54) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL30430145 | 0.91 | ROCK1 (0.54) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL19023118 | 0.85 | ROCK1 (0.68) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL17895393 | 0.84 | ROCK1 (0.48) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL30350735 | 0.83 | MEN1 (0.58) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL19510849 | 0.83 | MEN1 (0.58) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL19884907 | 0.78 | LTA4H (0.53) | LTA4H | |
| SCHEMBL1177375 | 0.76 | SLC6A2 (0.54) | ROCK1ROCK2PRKCDPRKACAPRKG1 | |
| SCHEMBL1177376 | 0.76 | SLC6A2 (0.54) | ROCK1ROCK2PRKCDPRKACAPRKG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180051031-A1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | THE SCRIPPS RESEARCH INSTITUTE | 2018-02-22 | — | — | US | disclosed |
| EP-1173432-B9 | PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY | NPS ALLELIX CORP (CA) | 2008-10-15 | — | — | EP | disclosed |
| EP-1173432-B1 | PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY | NPS ALLELIX CORP (CA) | 2007-10-17 | — | — | EP | disclosed |
| US-6562809-B1 | Contraction of coronary arteries may be mediated by its stimulation of the 5-HT1B (formerly 5-HT1D beta); compounds selective for a 5-HT1D receptor | NPS ALLELIX CORP. (CA) | 2003-05-13 | — | — | US | disclosed |
| EP-1114049-B1 | 3-BICYCLOINDOLE COMPOUNDS AS 5-HT1D RECEPTOR LIGANDS | NPS ALLELIX CORP (CA) | 2003-03-19 | — | — | EP | disclosed |
| US-6133287-A | SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS; CENTRAL NERVOUS SYSTEM DISORDERS, E.G., PSYCHOSIS, SCHIZOPHRENIA, MANIC DEPRESSION, DEPRESSION, MEMORY DISTURBANCES, PARKINSONISM, AMYLOTROPHIC LATERAL SCLEROSIS, ALZHEIMER'S AND HUNTINGTON'S DISEASE | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-10-17 | — | — | US | disclosed |
| US-6100291-A | FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2000-08-08 | — | — | US | disclosed |
| WO-1999047516-A1 | 3-(2-PYRROLIDINYLMETHYL)-INDOLE COMPOUNDS HAVING 5-HT6 AFFINITY | SLASSI ABDELMALIK (CA) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051031-A1 | SECO-CYCLOPROPAPYRROLOINDOLE COMPOUNDS, ANTIBODY-DRUG CONJUGATES THEREOF, AND METHODS OF MAKING AND USE | CD22, GDI2, GDI1 | ROCK1 957/4885ROCK2 1056/4885PRKCD 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.